{"entity":{"id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","aka":[],"tldr":"A phase 2 trial of Izalontamab brengitecan in chordoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma is a phase 2 interventional study registered as NCT06787664 by Sichuan Baili Pharmaceutical Co., Ltd., with 27 participants enrolled, started 2025-01-16 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1. Conditions listed: Chordoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06787664","url":"https://clinicaltrials.gov/study/NCT06787664"}],"tags":["ctgov-ingest"],"related":[],"cancers":["chordoma"],"sections":[],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06787664","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Locally Advanced or Metastatic Chordoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":27,"outcomes":[]},"route":"/trials/nct06787664/","neighbours":{"cancer":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}